Level 1 RC-02 Ozempic Revolution: A Miracle Drug or a Growing Ethical Dilemma?
- IIMwalaBanda
- Jul 25
- 3 min read
Updated: 3 days ago
A new class of drugs, originally developed to treat Type 2 diabetes, has unexpectedly become one of the world's most sought-after weight-loss treatments. Celebrities, influencers, and even ordinary consumers are embracing medications such as Ozempic and Wegovy, claiming dramatic reductions in body weight. The resulting surge in demand has transformed pharmaceutical companies into market giants while simultaneously raising difficult ethical questions.
Supporters argue that obesity is a chronic medical condition rather than a failure of willpower. For decades, doctors have advised patients to eat less and exercise more, yet long-term success has remained elusive for many. These new medications suppress appetite, improve blood sugar regulation, and have helped millions lose significant amounts of weight. Some researchers also believe they may reduce the risk of heart disease and other obesity-related illnesses. If effective treatment exists, proponents argue, denying patients access simply because the medicine appears "too easy" reflects outdated thinking about health.
Critics, however, warn that the growing popularity of these drugs is changing the very meaning of weight management. Social media has turned prescription medicines into lifestyle products, encouraging people with little medical need to seek rapid physical transformation. This has contributed to periodic shortages, leaving some diabetes patients struggling to obtain medication originally intended for their condition. Others question whether reliance on pharmaceutical solutions discourages healthier long-term habits involving nutrition, exercise, and behavioural change.
The debate extends beyond individual choices to broader questions of healthcare equity. These medicines remain expensive in many countries, placing them beyond the reach of lower-income populations who often experience higher rates of obesity. Consequently, a technology capable of improving public health may disproportionately benefit wealthier consumers, widening existing health inequalities. Policymakers therefore face a difficult balancing act: encouraging innovation while ensuring fair access.
For pharmaceutical companies, the success of weight-loss drugs represents one of the most lucrative opportunities in recent decades. Investors have rewarded manufacturers with soaring valuations, while competitors race to develop newer and potentially more effective treatments. Yet the commercial incentives also create concerns about aggressive marketing and over-medicalisation, where ordinary lifestyle challenges increasingly become opportunities for lifelong medication.
Ultimately, the Ozempic phenomenon illustrates a recurring dilemma in modern healthcare. Scientific breakthroughs often promise extraordinary benefits, but they also force societies to reconsider questions of fairness, responsibility, and the appropriate role of medicine. Whether these drugs are remembered primarily as a public health revolution or as a symbol of medicine's growing influence over everyday life may depend less on the drugs themselves than on how societies choose to regulate and distribute them.
Q1. The primary purpose of the passage is to
A. explain how Ozempic became the world's highest-selling pharmaceutical product.
B. examine the opportunities and ethical challenges arising from the growing use of weight-loss medications.
C. argue that governments should regulate pharmaceutical companies more strictly.
D. demonstrate why lifestyle changes are superior to medical interventions for obesity.
Q2. Which one of the following, if true, would most strengthen the critics' argument presented in the passage?
A. Clinical trials show that patients who combine medication with lifestyle changes achieve the best long-term outcomes.
B. A large proportion of healthy individuals are obtaining these medicines primarily for cosmetic weight loss, leading to persistent shortages for diabetes patients.
C. Pharmaceutical companies are investing heavily in developing next-generation obesity treatments.
D. Governments negotiate lower prices for essential medicines through public healthcare systems.
Q3. Which of the following can most reasonably be inferred from the passage?
A. Scientific innovation alone cannot determine whether a medical breakthrough benefits society.
B. Weight-loss medications will eventually replace exercise and dietary changes.
C. Obesity is caused primarily by poor lifestyle choices.
D. Pharmaceutical companies intentionally create medicine shortages to increase profits.
Q4. The author's attitude towards the widespread use of weight-loss drugs is best described as
A. enthusiastic, because these medicines represent the future of healthcare.
B. sceptical, because pharmaceutical companies cannot be trusted.
C. balanced, acknowledging both the transformative potential and the ethical dilemmas associated with these medicines.
D. dismissive, because lifestyle changes remain the only effective solution.
Q4. Correct Answer: C
Why C is correct:The author presents both the benefits and the concerns associated with these medicines without taking a strong position. The tone remains analytical and balanced throughout the passage.
Why A is incorrect:The author acknowledges the medical benefits but also highlights concerns about affordability, shortages, ethics, and commercialization. This is far from enthusiastic endorsement.
Why B is incorrect:The passage discusses commercial incentives but never suggests that pharmaceutical companies are inherently untrustworthy. This option overstates the author's position.
Why D is incorrect:The author never dismisses these medicines. On the contrary, the passage recognizes their significant medical value while discussing their broader implications.
Q3. Correct Answer: A
Why A is correct:The final paragraph suggests that the ultimate impact of these medicines depends not only on scientific innovation but also on regulation, accessibility, and societal choices. Therefore, science alone is insufficient to determine social benefit.
Why B is incorrect:The passage never suggests that medications will replace healthy habits. In fact, it mentions concerns that reliance on drugs could discourage lifestyle changes, which is very different.
Why C is incorrect:The passage explicitly challenges simplistic views of obesity and presents it as a complex medical condition. This option contradicts the author's discussion.
Why D is incorrect:Although the passage discusses commercial incentives, it never accuses companies of deliberately creating shortages. This is an unsupported and extreme inference.
Q2. Correct Answer: B
Why B is correct:The critics argue that people without medical necessity are using these drugs, creating shortages for diabetes patients. This option provides direct evidence supporting that concern, making it the strongest strengthening statement.
Why A is incorrect:This discusses the effectiveness of combining medication with lifestyle changes. It neither supports nor weakens the critics' concern about misuse or shortages.
Why C is incorrect:Investment in new drugs relates to innovation and business growth. It says nothing about the ethical issues raised by the critics.
Why D is incorrect:Lower prices may improve affordability, but this option does not address the critics' concerns regarding inappropriate usage or shortages.
Q1. Correct Answer: B
Why B is correct:The passage explores multiple dimensions of weight-loss drugs—medical benefits, ethical concerns, healthcare inequality, and commercial incentives. It does not advocate one position but examines the broader implications of their increasing use. This captures the overall purpose of the passage.
Why A is incorrect:Although the passage mentions the commercial success of these drugs, it is only one aspect of a much broader discussion. The passage is not primarily about the business success of Ozempic.
Why C is incorrect:The passage discusses regulation but never argues that stricter regulation is the solution. It presents regulation as one of several considerations rather than its central argument.
Why D is incorrect:The passage explicitly acknowledges the effectiveness of these…